X4 Pharmaceuticals Inc (XFOR) — Cash Flow-to-Debt Ratio
X4 Pharmaceuticals Inc (XFOR) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of $-20.79 Million could theoretically repay 0% of its total liabilities ($97.61 Million) in one year. See XFOR financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
X4 Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for X4 Pharmaceuticals Inc across 11 annual periods. For the full cash flow conversion analysis, see X4 Pharmaceuticals Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for X4 Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for X4 Pharmaceuticals Inc. Check X4 Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-85.62 Million | $104.17 Million | ▲ +22.0% |
| 2024 | -1.05x | $-130.90 Million | $124.30 Million | ▼ -4.9% |
| 2023 | -1.00x | $-96.51 Million | $96.16 Million | ▼ -6.1% |
| 2022 | -0.95x | $-77.10 Million | $81.53 Million | ▲ +29.6% |
| 2021 | -1.34x | $-70.91 Million | $52.76 Million | ▼ -14.4% |
| 2020 | -1.17x | $-58.82 Million | $50.07 Million | ▲ +23.1% |
| 2019 | -1.53x | $-48.05 Million | $31.48 Million | ▲ +13.5% |
| 2018 | -1.76x | $-25.42 Million | $14.40 Million | ▼ -42.8% |
| 2017 | -1.24x | $-27.87 Million | $22.55 Million | ▼ -39.0% |
| 2016 | -0.89x | $-21.64 Million | $24.33 Million | ▼ -14.2% |
| 2015 | -0.78x | $-10.82 Million | $13.88 Million | — |